GULBARGA UNIVERSITY, KALABURAGI Institutional Repository
Please use this identifier to cite or link to this item:
http://gukir.inflibnet.ac.in:8080/jspui/handle/123456789/5657Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Hooper M | |
| dc.contributor.author | Purohit M.G. | |
| dc.date.accessioned | 2020-06-12T15:08:26Z | - |
| dc.date.available | 2020-06-12T15:08:26Z | - |
| dc.date.issued | 1983 | |
| dc.identifier.citation | Progress in Medicinal Chemistry , Vol. 20 , C , p. 1 - 81 | en_US |
| dc.identifier.uri | 10.1016/S0079-6468(08)70216-9 | |
| dc.identifier.uri | http://gukir.inflibnet.ac.in:8080/jspui/handle/123456789/5657 | - |
| dc.description.abstract | This chapter presents a critical assessment of the chemotherapy of leprosy referring to both ancient and more recent drugs. In the light of the growing understanding of Mycobacterium leprae and the disease of leprosy, suggestions have been made about possible ways new drugs might be developed. The chapter summarizes the major features of the disease (leprosy). Leprosy is commonly regarded as one of the oldest diseases known to mankind. The treatment of leprosy sufferers has long been the object of certain missionary, charitable and voluntary societies. It is a disease of skin and peripheral nerves caused by Mycobucterium leprue. The major features of M. leprue are summarized in this chapter. A variety of second line drugs are recognized as useful therapeutic agents, including thiambutosine, prothionamide, ethionamide, and thiacetazone. © 1983, Elsevier B.V. All rights reserved. | en_US |
| dc.title | The chemotherapy of leprosy | en_US |
| dc.type | Article | |
| Appears in Collections: | 1. Journal Articles | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.